Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical impact, and management

Garg, Lohit; Gupta, Manasvi; Sabzwari, Syed Rafay Ali; Agrawal, Sahil; Agarwal, Manyoo; Nazir, Talha; Gordon, James M.; Bozorgnia, Babak; Martinez, Matthew W.

doi:10.1007/s10741-018-9752-6

Cited by 49 publications

(45 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is also interesting to note that, among the events on follow-up, hospitalization associated with new-onset atrial fibrillation was especially more frequent in the detected group. As atrial fibrillation is gaining more attention as a problem of morbidity and an initiating cause of heart failure and stroke in HCM [45,46], more studies will be needed to address the association of genetic variants and atrial fibrillation.…”

Section: Discussionmentioning

confidence: 99%

Genotype-Related Clinical Characteristics and Myocardial Fibrosis and Their Association with Prognosis in Hypertrophic Cardiomyopathy

Kim

Park

Lee

et al. 2020

JCM

View full text Add to dashboard Cite

Background: The spectrum of genetic variants and their clinical significance of Hypertrophic cardiomyopathy (HCM) have been poorly studied in Asian patients. The objectives of this study were to assess the spectrum of genetic variants and genotype–phenotype relationships within a Korean HCM population. Methods: Eighty-nine consecutive unrelated HCM patients were included. All patients underwent genotypic analysis for 23 HCM-associated genes. Clinical parameters including echocardiographic and cardiac magnetic resonance (CMR) parameters were evaluated. A composite of major adverse cardiac and cerebrovascular events was assessed. Results: Genetic variants were detected in 55 of 89 subjects. Pathogenic variants or likely pathogenic variants were identified in 27 of HCM patients in MYBPC3, TNNI3, MYH7, and MYL7. Variants of uncertain significance were identified in 28 patients. There were significant differences in the presence of non-sustained ventricular tachycardia (p = 0.030) and myocardial fibrosis on CMR (p = 0.029) in the detected compared to the not-detected groups. Event-free survival was superior in the not-detected group (p = 0.006). Conclusion: Genetic variants in patients with HCM are relatively common and are associated with adverse clinical events and myocardial fibrosis on CMR. Genotypic analysis may add important information to clinical variables in the assessment of long-term risk for HCM patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Genotype-Related Clinical Characteristics and Myocardial Fibrosis and Their Association with Prognosis in Hypertrophic Cardiomyopathy

Kim

Park

Lee

et al. 2020

JCM

View full text Add to dashboard Cite

show abstract

“…Previous studies have shown that annual AF development incidence in HCM patients is 2-4%; this incidence is 20-30% throughout life, and it can increase to rates of up to 40% in patients older than 70 years old. 16,17 . In our study, this rate was found to be 16.9%.…”

Section: Resultsmentioning

confidence: 99%

Left Atrial Dispersion Predicts Atrial Fibrillation in Patients with Hypertrophic Cardiomyopathy: A 5-year Follow-up study

Candan

Çakmak

Geçmen

et al. 2020

Preprint

View full text Add to dashboard Cite

Purpose:The aim of our study was to examine whether left atrial dispersion and left atrial strain as measured by speckle tracking echocardiography and clinic paramaters are predictors for the development of atrial fibrillation (AF) in patients with hypertrophic cardiomyopathy. Methods: A total of 137 patients (70% male, mean age 49.6 ± 14.2 years) with HCM were included in the study. Patients' clinical, electrocardiographic, 2D classic and speckle tracking echocardiographic (STE) data were collected. AF was searched by 12-lead electrocardiograms or 24-hour Holter recordings during follow-up period. Atrial dispersion was defined as the standard deviation of time to peak strain in 12 left atrial segments Results: During a follow-up period of 5 years 37 patients (16.9%) developed AF. At follow-up, the patients with occurrence of AF were older than in patients without AF. Atrial dispersion was observed to be higher in the AF developing group (61.4 ± 23.2 vs 43.1±15.8, p=<0.001). The multivariate in Cox regression analysis (including atrial dispersion, PALS, age, LA) atrial dispersion (msn) (HR 1.017, 95% CI: 1.001-1.03, p= 0.035) and age were found to be independent predictors of AF occurrence. In the ROC analysis atrial dispersion > 44.7 msn predicted occurrence of AF with 82.4% sensitivity and 64 % specificity. Conclusion: In patients with hypertrophic cardiomyopathy, atrial dispersion and age are predictive of the development of atrial fibrillation. Atrial dispersion measured by the speckle tracking-based method may provide further information in evaluating left atrial functions in patients with hypertrophic cardiomyopathy or other disease states

show abstract

“…Persistent AF was found in 50% of patients having thromboembolism [18], while paroxysmal AF was reported in 11 out of 18 in the thromboembolic patients [39]. However, the incidence of thromboembolism between HCM patients with paroxysmal AF and those with chronic AF was reported not significantly different [33,40], and the thromboembolism risk in AF is not related to the number of paroxysms as well [41].…”

Section: Atrial Fibrillationmentioning

confidence: 90%

Thromboembolism in Patients with Hypertrophic Cardiomyopathy

Liu

Chen

et al. 2021

Int. J. Med. Sci.

View full text Add to dashboard Cite

Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical impact, and management

Cited by 49 publications

References 63 publications

Genotype-Related Clinical Characteristics and Myocardial Fibrosis and Their Association with Prognosis in Hypertrophic Cardiomyopathy

Genotype-Related Clinical Characteristics and Myocardial Fibrosis and Their Association with Prognosis in Hypertrophic Cardiomyopathy

Left Atrial Dispersion Predicts Atrial Fibrillation in Patients with Hypertrophic Cardiomyopathy: A 5-year Follow-up study

Thromboembolism in Patients with Hypertrophic Cardiomyopathy

Contact Info

Product

Resources

About